BofA analyst Jason Gerberry raised the firm’s price target on Intra-Cellular to $91 from $82 and keeps a Buy rating on the shares after the company reported positive Phase 3 topline results from its first MDD trial assessing Caplyta as an adjunctive therapy. The firm estimates MDD plus mixed features could add $1.1B in nominal peak sales given the large addressable market and Caplyta’s differentiated tolerability profile, the analyst tells investors.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ITCI:
- Intra-Cellular Therapies Announces Proposed Public Offering of Common Stock
- Intra-Cellular Advances Depression Treatment with Lumateperone
- Intra-Cellular Therapies Announces Positive Phase 3 Topline Results from Study 501 Evaluating Lumateperone as Adjunctive Therapy in Patients with Major Depressive Disorder
- Needham remains positive on Intra-Cellular ahead of Caplyta readouts
- Intra-Cellular Therapies Announces Executive Leadership Changes
